Alpha-dystroglycan Binding Peptide A2G80-modified Stealth Liposomes as a Muscle-targeting Carrier for Duchenne Muscular Dystrophy

Authors: E. Sasaki, Y. Hayashi, Y. Kimura, S. Sashida, N. Hamano, Y. Negishi et. al.

Journal: Journal of Controlled Release

DOI: 10.1016/j.jconrel.2020.10.032

Publication - Abstract

October 17, 2020

SHARE

Other Payloads Liposomes Other Applications

Abstract

Safe and efficient gene therapy for the treatment of Duchenne muscular dystrophy (DMD), a genetic disorder, is required. For this, the muscle-targeting delivery system of genes and nucleic acids is ideal. In this study, we focused on the A2G80 peptide, which has an affinity for α-dystroglycan expressed on muscle cell membranes, as a muscle targeted nanocarrier for DMD and developed A2G80-modified liposomes. We also prepared A2G80-modified liposomes coated with long- and short-chain PEG, called A2G80-LSP-Lip, to improve the blood circulation of liposomes using microfluidics.

The liposomes had a particle size of approximately 80 nm. A2G80-LSP-Lip showed an affinity for the muscle tissue section of mice by overlay assay. When the liposomes were administered to DMD model mice (mdx mice) via the tail vein, A2G80-LSP-Lip accumulated efficiently in muscle tissue compared to control liposomes. These results suggest that A2G80-LSP-Lip can function as a muscle-targeting liposome for DMD via systemic administration, and may be a useful tool for DMD treatment.

Alpha-dystroglycan Binding Peptide A2G80-modified Stealth Liposomes as a Muscle-targeting Carrier for Duchenne Muscular Dystrophy

Abstract

Advanced Search

Browse by Category

related content

Advances in Development of mRNA-Based Therapeutics

Microfluidic-assisted Silk Nanoparticle Tuning